The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 28, 2009
Filed:
Feb. 01, 2008
Simon James Anthony Grove, Newhouse, GB;
Julia Adam-worrall, Newhouse, GB;
Mingqiang Zhang, Kirkland, CA;
Robert Gilfillan, Newhouse, GB;
Simon James Anthony Grove, Newhouse, GB;
Julia Adam-Worrall, Newhouse, GB;
Mingqiang Zhang, Kirkland, CA;
Robert Gilfillan, Newhouse, GB;
N.V. Organon, Oss, NL;
Abstract
The present invention relates to (pyrido/thieno)-[f]-oxazepine-5-one derivatives having the general Formula I wherein R, Rand Rare independently H or (C)alkyl; Ar represents a fused thiophene or pyridine ring optionally substituted with one or more substituents selected from (C)alkyl, (C)alkyloxy, (C)alkyloxy(C)alkyl, CF, halogen, nitro, cyano, NRR, NRCOR, and CONRR; Rand Rare independently H or (C)alkyl; or Rand Rform together with the nitrogen atom to which they are bound a 5- or 6-membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O, S or NR; Ris (C)alkyl; A represents the residue of a 4-7 membered saturated heterocyclic ring, optionally containing an oxygen atom, the ring being optionally substituted with 1-3 substituents selected from (C)alkyl, (C)alkyloxy, hydroxy, halogen and oxo; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these (pyrido/thieno)-[f]-oxazepine-5-one derivatives in the treatment of neurological diseases and psychiatric disorders which are responsive to enhancement of synaptic responses mediated by AMPA receptors in the central nervous system.